Text Size

Effect of NN5401 in Japanese Subjects With Type 1 Diabetes

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk
ClinicalTrials.gov Identifier:
NCT01051102
First received: January 15, 2010
Last updated: June 28, 2012
Last verified: May 2012
History of Changes
  Purpose

This trial is conducted in Japan. The aim of this clinical trial is to investigate the blood sugar lowering effect of NN5401 in Japanese subjects with type 1 diabetes. Each subject will be randomised to one of the two possible treatment sequences (NN5401 followed by biphasic insulin aspart 30 or biphasic insulin aspart 30 followed by NN5401).


Condition Intervention Phase
Diabetes
Diabetes Mellitus, Type 1
 Drug: NN5401
Drug: biphasic insulin aspart 30
 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Trial Investigating the Pharmacodynamic Properties of NN5401 in Japanese Subjects With Type 1 Diabetes

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Novo Nordisk:

Primary Outcome Measures:
  • Area under the Glucose Infusion Rate curve after a single dose [ Time Frame: from 4-12 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Area under the insulin aspart concentration-time curve after a single dose [ Time Frame: from 0-12 hours ] [ Designated as safety issue: No ]

Enrollment: 29
Study Start Date: January 2010
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: NN5401
Single dose of 0.5 U/kg body weight injected s.c. (under the skin)"
Active Comparator: B Drug: biphasic insulin aspart 30
Single dose of 0.5 U/kg body weight injected s.c. (under the skin)

  Eligibility

Ages Eligible for Study:   20 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 1 diabetes mellitus for at least 12 months
  • Body mass index (BMI): 18-28 kg/m2 (both inclusive)

Exclusion Criteria:

  • Loss of more than 400 mL blood in total within the last 12 weeks or more than 200 mL blood in total within the last 4 weeks prior to study start
  • Smoking more than 5 cigarettes or the equivalent per day
  • Not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01051102

Locations
Japan
Tokyo, Japan, 130-0004
Sponsors and Collaborators
Novo Nordisk
Investigators
Study Director: Tomio Sasaki Novo Nordisk Pharma Ltd.
Study Director: Takahiro Terakawa Novo Nordisk Pharma Ltd.
  More Information

Additional Information:
Clinical Trials at Novo Nordisk  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Novo Nordisk
ClinicalTrials.gov Identifier: NCT01051102     History of Changes
Other Study ID Numbers: NN5401-1983, U1111-1112-3698
Study First Received: January 15, 2010
Last Updated: June 28, 2012
Health Authority: Japan: Ministry of Health, Labor and Welfare

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
 Immune System Diseases
Insulin aspart
Insulin, NPH
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 16, 2013